1.
Yamashita Y, Hori Y, Kosako H, Oiwa T, Warigaya K, Mushino T, Murata S, Fujimoto M, Nishikawa A, Murata S- ichi, Sonoki T, Tamura S. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with <em>RUNX3</em&gt; overexpression. Hematol Rep [Internet]. 2020May15 [cited 2020Sep.22];12(1). Available from: https://www.pagepress.org/journals/index.php/hr/article/view/8368